iGan Partners Portfolio Update: Momentum Across Medtech and Health Data
iGan Partners Portfolio Update: Momentum Across Medtech and Health Data
PR Newswire
TORONTO, Sept. 11, 2026
TORONTO, Sept. 11, 2026 /PRNewswire/ -- iGan Partners, a Toronto-based venture capital firm investing in medical device, diagnostic, imaging, and digital health companies, today shared recent milestones from across its portfolio.
Flosonics Medical announced a development contract, valued at up to $70 million, with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The contract includes initial funding of approximately $15 million and supports FloPredict, an AI-enabled software enhancement to the company's FDA-cleared FloPatch device, extending the company's real-time ultrasound technology into trauma care and mass casualty response.
Exact Imaging delivered 166% year-over-year revenue growth in its first 12 months following a strategic transition from a single international distribution model to a direct sales and expanded distribution network approach. The company also strengthened its North American direct sales team, and the body of peer-reviewed literature supporting ExactVu now exceeds 140 published papers.
MolecuLight and The Royal Orthopaedic Hospital NHS Foundation Trust announced the publication of the first clinical study evaluating fluorescence imaging during orthopaedic surgery. The prospective 10-patient pilot extends MolecuLight's clinical evidence base beyond chronic wound care into perioperative surgical applications.
Cosm Medical entered a licensing and collaboration agreement with Duke Health and Mayo Clinic to develop and commercialize Gynethotics Recovery, a new class of personalized devices for recovery after pelvic reconstructive surgery, built on Cosm's digital gynecology platform combining medical imaging and 3D printing.
Marble launched a dedicated medical records service for claimants under the Pan-Canadian Claimants' Compensation Plan, the $2.521 billion fund for eligible claimants outside Quebec under Canada's tobacco settlement, working with plan agent Epiq to gather the medical evidence eligibility turns on.
Segmed provided the data behind a new paper with Stanford University and the University of Washington School of Medicine, published in The International Journal of Cardiovascular Imaging, which tested 54 large language model configurations on cardiac imaging reports and found that open-weight models can approach the agreement of expert radiologists.
SOURCE iGan Partners
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
4 Stocks to Buy Before They Rise Further
The Top Funds for a Simpler Retirement Portfolio
United States